{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:34:21Z","timestamp":1787002461104,"version":"build-2736575974"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1038\/ncpuro0995","type":"journal-article","created":{"date-parts":[[2008,1,9]],"date-time":"2008-01-09T11:33:09Z","timestamp":1199878389000},"page":"24-34","source":"Crossref","is-referenced-by-count":85,"title":["Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?"],"prefix":"10.1038","volume":"5","author":[{"given":"Celestia S","family":"Higano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpuro0995_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A  et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43\u201366","journal-title":"CA Cancer J Clin"},{"key":"BFncpuro0995_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ucl.2004.01.001","volume":"31","author":"CS Higano","year":"2004","unstructured":"Higano CS (2004) Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin N Am 31: 331\u2013352","journal-title":"Urol Clin N Am"},{"key":"BFncpuro0995_CR3","unstructured":"The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology (version 2.2007). \u00a9 2006 National Comprehensive Cancer Network, Inc. [\n                    http:\/\/www.nccn.org\n                    \n                  ] (accessed 15 May 2007)"},{"key":"BFncpuro0995_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","volume":"360","author":"M Bolla","year":"2002","unstructured":"Bolla M  et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103\u2013108","journal-title":"Lancet"},{"key":"BFncpuro0995_CR5","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","volume":"61","author":"MV Pilepich","year":"2005","unstructured":"Pilepich MV  et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61: 1285\u20131290","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFncpuro0995_CR6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jama.292.7.821","volume":"292","author":"AV D'Amico","year":"2004","unstructured":"D'Amico AV  et al. (2004) 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292: 821\u2013827","journal-title":"JAMA"},{"key":"BFncpuro0995_CR7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","volume":"7","author":"EM Messing","year":"2006","unstructured":"Messing EM  et al. (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7: 472\u2013479","journal-title":"Lancet Oncol"},{"key":"BFncpuro0995_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.eururo.2006.03.001","volume":"50","author":"B Pettersson","year":"2006","unstructured":"Pettersson B  et al. (2006) Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate: 12-month follow-up study. Eur Urol 50: 483\u2013489","journal-title":"Eur Urol"},{"key":"BFncpuro0995_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1464-410X.2005.05565.x","volume":"96","author":"VA Jenkins","year":"2005","unstructured":"Jenkins VA  et al. (2005) Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 96: 48\u201353","journal-title":"BJU Int"},{"key":"BFncpuro0995_CR10","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S0022-5347(05)67533-7","volume":"163","author":"HW Herr","year":"2000","unstructured":"Herr HW  et al. (2000) Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163: 1743\u20131746","journal-title":"J Urol"},{"key":"BFncpuro0995_CR11","first-page":"465","volume":"166","author":"VB Shahinian","year":"2006","unstructured":"Shahinian VB  et al. (2006) Risk of \u201candrogen deprivation syndrome\u201d in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166: 465\u2013471","journal-title":"Arch Intern Med"},{"key":"BFncpuro0995_CR12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/00007611-199809000-00010","volume":"91","author":"DA Schow","year":"1998","unstructured":"Schow DA  et al. (1998) Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 91: 855\u2013857","journal-title":"South Med J"},{"key":"BFncpuro0995_CR13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/jnci\/94.6.430","volume":"94","author":"AL Potosky","year":"2002","unstructured":"Potosky AL  et al. (2002) Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 94: 430\u2013437","journal-title":"J Natl Cancer Inst"},{"key":"BFncpuro0995_CR14","first-page":"2547","volume":"12","author":"R Choo","year":"2005","unstructured":"Choo R  et al. (2005) How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients. Can J Urol 12: 2547\u20132552","journal-title":"Can J Urol"},{"key":"BFncpuro0995_CR15","first-page":"1757","volume":"23","author":"J Bogdanos","year":"2003","unstructured":"Bogdanos J  et al. (2003) Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement. Anticancer Res 23: 1757\u20131762","journal-title":"Anticancer Res"},{"key":"BFncpuro0995_CR16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1210\/jc.2005-2507","volume":"91","author":"MR Smith","year":"2006","unstructured":"Smith MR  et al. (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91: 1305\u20131308","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpuro0995_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","volume":"161","author":"JF Maillefert","year":"1999","unstructured":"Maillefert JF  et al. (1999) Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161: 1219\u20131222","journal-title":"J Urol"},{"key":"BFncpuro0995_CR18","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","volume":"87","author":"D Mittan","year":"2002","unstructured":"Mittan D  et al. (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87: 3656\u20133661","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpuro0995_CR19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","volume":"176","author":"CW Ryan","year":"2006","unstructured":"Ryan CW  et al. (2006) Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176: 972\u2013978","journal-title":"J Urol"},{"key":"BFncpuro0995_CR20","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"MD Michaelson","year":"2007","unstructured":"Michaelson MD  et al. (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist\u2013induced bone loss in men with prostate cancer. J Clin Oncol 25: 1038\u20131042","journal-title":"J Clin Oncol"},{"key":"BFncpuro0995_CR21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"345","author":"MR Smith","year":"2001","unstructured":"Smith MR  et al. (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345: 948\u2013955","journal-title":"N Engl J Med"},{"key":"BFncpuro0995_CR22","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","volume":"167","author":"A Berruti","year":"2002","unstructured":"Berruti A  et al. (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167: 2361\u20132367","journal-title":"J Urol"},{"key":"BFncpuro0995_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","volume":"5","author":"RS Israeli","year":"2007","unstructured":"Israeli RS  et al. (2007) The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 5: 271\u2013277","journal-title":"Clin Genitourin Cancer"},{"key":"BFncpuro0995_CR24","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR  et al. (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008\u20132012","journal-title":"J Urol"},{"key":"BFncpuro0995_CR25","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL  et al. (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90: 6410\u20136417","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpuro0995_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL  et al. (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146: 416\u2013424","journal-title":"Ann Intern Med"},{"key":"BFncpuro0995_CR27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.hoc.2006.03.013","volume":"20","author":"C Higano","year":"2006","unstructured":"Higano C (2006) Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin N Am 20: 909\u2013923","journal-title":"Hematol Oncol Clin N Am"},{"key":"BFncpuro0995_CR28","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1464-410X.2005.05399.x","volume":"95","author":"R Weston","year":"2005","unstructured":"Weston R  et al. (2005) Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone\u2013releasing hormone analogue therapy in osteoporotic patients with prostate cancer. BJU Int 95: 776\u2013779","journal-title":"BJU Int"},{"key":"BFncpuro0995_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/pros.20341","volume":"66","author":"H Kaku","year":"2005","unstructured":"Kaku H  et al. (2005) Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 66: 439\u2013444","journal-title":"Prostate"},{"key":"BFncpuro0995_CR30","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0022-5347(05)66910-8","volume":"164","author":"RJ Nejat","year":"2000","unstructured":"Nejat RJ  et al. (2000) A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164: 1891\u20131894","journal-title":"J Urol"},{"key":"BFncpuro0995_CR31","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1097\/01.ju.0000154780.72631.85","volume":"173","author":"JL Gulley","year":"2005","unstructured":"Gulley JL  et al. (2005) A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 173: 1567\u20131571","journal-title":"J Urol"},{"key":"BFncpuro0995_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","volume":"23","author":"BL Riggs","year":"2002","unstructured":"Riggs BL  et al. (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23: 279\u2013302","journal-title":"Endocr Rev"},{"key":"BFncpuro0995_CR33","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1359\/jbmr.060508","volume":"21","author":"R Eastell","year":"2006","unstructured":"Eastell R  et al. (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res 21: 1215\u20131223","journal-title":"J Bone Miner Res"},{"key":"BFncpuro0995_CR34","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","volume":"14","author":"I Fogelman","year":"2003","unstructured":"Fogelman I  et al. (2003) Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 14: 1001\u20131006","journal-title":"Osteoporos Int"},{"key":"BFncpuro0995_CR35","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.urology.2004.07.019","volume":"64","author":"C Higano","year":"2004","unstructured":"Higano C  et al. (2004) Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 64: 1182\u20131186","journal-title":"Urology"},{"key":"BFncpuro0995_CR36","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR  et al. (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23: 7897\u20137903","journal-title":"J Clin Oncol"},{"key":"BFncpuro0995_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB  et al. (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352: 154\u2013164","journal-title":"N Engl J Med"},{"key":"BFncpuro0995_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","volume":"175","author":"MR Smith","year":"2006","unstructured":"Smith MR  et al. (2006) Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175: 136\u2013139","journal-title":"J Urol"},{"key":"BFncpuro0995_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","volume":"34","author":"SCE Schuit","year":"2004","unstructured":"Schuit SCE  et al. (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34: 195\u2013202","journal-title":"Bone"},{"key":"BFncpuro0995_CR40","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s001980170017","volume":"12","author":"JD Adachi","year":"2001","unstructured":"Adachi JD  et al. (2001) The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 12: 903\u2013908","journal-title":"Osteoporos Int"},{"key":"BFncpuro0995_CR41","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR  et al. (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353: 878\u2013882","journal-title":"Lancet"},{"key":"BFncpuro0995_CR42","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/ard.59.10.765","volume":"59","author":"JM Kaufman","year":"2000","unstructured":"Kaufman JM  et al. (2000) Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 59: 765\u2013772","journal-title":"Ann Rheum Dis"},{"key":"BFncpuro0995_CR43","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1200\/JCO.2006.07.5382","volume":"24","author":"AJ Chien","year":"2006","unstructured":"Chien AJ  et al. (2006) Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24: 5305\u20135312","journal-title":"J Clin Oncol"},{"key":"BFncpuro0995_CR44","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0302-2838(03)00379-8","volume":"44","author":"J Morote","year":"2003","unstructured":"Morote J  et al. (2003) Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 44: 661\u2013665","journal-title":"Eur Urol"},{"key":"BFncpuro0995_CR45","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","volume":"69","author":"J Morote","year":"2007","unstructured":"Morote J  et al. (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69: 500\u2013504","journal-title":"Urology"},{"key":"BFncpuro0995_CR46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.urology.2007.03.026","volume":"70","author":"CW Ryan","year":"2007","unstructured":"Ryan CW  et al. (2007) Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70: 122\u2013126","journal-title":"Urology"},{"key":"BFncpuro0995_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","volume":"57","author":"J Kiratli","year":"2001","unstructured":"Kiratli J  et al. (2001) Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57: 127\u2013132","journal-title":"Urology"},{"key":"BFncpuro0995_CR48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0889-8529(05)70005-0","volume":"27","author":"GM Blake","year":"1998","unstructured":"Blake GM  et al. (1998) Applications of bone densitometry for osteoporosis. Endocrinol Metab Clin North Am 27: 267\u2013288","journal-title":"Endocrinol Metab Clin North Am"},{"key":"BFncpuro0995_CR49","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/cncr.21047","volume":"103","author":"MM Agarwal","year":"2005","unstructured":"Agarwal MM  et al. (2005) Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 103: 2042\u20132052","journal-title":"Cancer"},{"key":"BFncpuro0995_CR50","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.urology.2004.03.036","volume":"64","author":"FA Conde","year":"2004","unstructured":"Conde FA  et al. (2004) Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology 64: 335\u2013340","journal-title":"Urology"},{"key":"BFncpuro0995_CR51","first-page":"1366","volume-title":"Cecil Textbook of Medicine","author":"JS Finkelstein","year":"2000","unstructured":"Finkelstein JS (2000) Osteoporosis. In Cecil Textbook of Medicine, 1366\u20131373 (Eds Goldman L  et al.) Philadelphia: WB Saunders Company"},{"key":"BFncpuro0995_CR52","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","volume":"91","author":"MR Smith","year":"2001","unstructured":"Smith MR  et al. (2001) Low bone mineral density in hormone-na\u00efve men with prostate carcinoma. Cancer 91: 2238\u20132245","journal-title":"Cancer"},{"key":"BFncpuro0995_CR53","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/j.1464-410X.2006.06695.x","volume":"99","author":"J Planas","year":"2007","unstructured":"Planas J  et al. (2007) The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int 99: 812\u2013816","journal-title":"BJU Int"},{"key":"BFncpuro0995_CR54","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s001980170006","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA  et al. (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12: 989\u2013995","journal-title":"Osteoporos Int"},{"key":"BFncpuro0995_CR55","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1359\/jbmr.2000.15.2.183","volume":"15","author":"KG Faulkner","year":"2000","unstructured":"Faulkner KG (2000) Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 15: 183\u2013187","journal-title":"J Bone Miner Res"},{"key":"BFncpuro0995_CR56","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1359\/jbmr.060708","volume":"21","author":"SR Cummings","year":"2006","unstructured":"Cummings SR  et al. (2006) BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 21: 1550\u20131556","journal-title":"J Bone Miner Res"},{"key":"BFncpuro0995_CR57","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","volume":"286","author":"ES Siris","year":"2001","unstructured":"Siris ES  et al. (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the national osteoporosis risk assessment. JAMA 286: 2815\u20132822","journal-title":"JAMA"},{"key":"BFncpuro0995_CR58","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/PL00004177","volume":"11","author":"PL Selby","year":"2000","unstructured":"Selby PL  et al. (2000) Do men and women fracture bones at similar bone densities? Osteoporos Int 11: 153\u2013157","journal-title":"Osteoporos Int"},{"key":"BFncpuro0995_CR59","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00198-004-1694-2","volume":"16","author":"LS Orsini","year":"2005","unstructured":"Orsini LS  et al. (2005) Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int 16: 359\u2013371","journal-title":"Osteoporos Int"},{"key":"BFncpuro0995_CR60","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1200\/JCO.2003.09.534","volume":"21","author":"RJ Segal","year":"2003","unstructured":"Segal RJ  et al. (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21: 1653\u20131659","journal-title":"J Clin Oncol"},{"key":"BFncpuro0995_CR61","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1007\/s00198-005-1949-6","volume":"16","author":"AM Sawka","year":"2005","unstructured":"Sawka AM  et al. (2005) Health-related quality of life measurements in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 16: 1836\u20131840","journal-title":"Osteoporos Int"},{"key":"BFncpuro0995_CR62","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R  et al. (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res 22: 465\u2013475","journal-title":"J Bone Miner Res"},{"key":"BFncpuro0995_CR63","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/archinte.162.19.2217","volume":"162","author":"GM Kiebzak","year":"2002","unstructured":"Kiebzak GM  et al. (2002) Undertreatment of osteoporosis in men with hip fractures. Arch Intern Med 162: 2217\u20132222","journal-title":"Arch Intern Med"},{"key":"BFncpuro0995_CR64","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/0003-4819-129-2-199807150-00002","volume":"129","author":"EW Gregg","year":"1998","unstructured":"Gregg EW  et al. (1998) Physical activity and osteoporotic fractures risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 129: 81\u201388","journal-title":"Ann Intern Med"},{"key":"BFncpuro0995_CR65","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B  et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282: 637\u2013645","journal-title":"JAMA"},{"key":"BFncpuro0995_CR66","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00296-003-0388-y","volume":"24","author":"JD Ringe","year":"2004","unstructured":"Ringe JD  et al. (2004) Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24: 110\u2013113","journal-title":"Rheumatol Int"},{"key":"BFncpuro0995_CR67","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM  et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809\u20131822","journal-title":"N Engl J Med"},{"key":"BFncpuro0995_CR68","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1056\/NEJM199709043371003","volume":"337","author":"B Dawson-Hughes","year":"1997","unstructured":"Dawson-Hughes B  et al. (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 337: 670\u2013676","journal-title":"N Engl J Med"},{"key":"BFncpuro0995_CR69","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1210\/jc.2003-032058","volume":"89","author":"MR Smith","year":"2004","unstructured":"Smith MR  et al. (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89: 3841\u20133846","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpuro0995_CR70","doi-asserted-by":"publisher","first-page":"534","DOI":"10.2146\/ajhp050045.p2","volume":"63","author":"LB Michaud","year":"2006","unstructured":"Michaud LB  et al. (2006) Cancer-treatment-induced bone loss, part 2. Am J Health-Syst Pharm 63: 534\u2013546","journal-title":"Am J Health-Syst Pharm"},{"key":"BFncpuro0995_CR71","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/cncr.20056","volume":"100","author":"TH Diamond","year":"2004","unstructured":"Diamond TH  et al. (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100: 892\u2013899","journal-title":"Cancer"},{"key":"BFncpuro0995_CR72","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","volume":"359","author":"PD Delmas","year":"2002","unstructured":"Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359: 2018\u20132026","journal-title":"Lancet"},{"key":"BFncpuro0995_CR73","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0002-9343(99)80310-6","volume":"98","author":"IR Reid","year":"1995","unstructured":"Reid IR  et al. (1995) Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 98: 331\u2013335","journal-title":"Am J Med"},{"key":"BFncpuro0995_CR74","first-page":"3011","volume":"85","author":"M Peacock","year":"2000","unstructured":"Peacock M  et al. (2000) Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 85: 3011\u20133019","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpuro0995_CR75","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF00298427","volume":"57","author":"S Eriksson","year":"1999","unstructured":"Eriksson S  et al (1999) Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57: 97\u201399","journal-title":"Calcif Tissue Int"},{"key":"BFncpuro0995_CR76","unstructured":"Fosamax\u00ae package insert (Merck & Co, Inc. 2006)"},{"key":"BFncpuro0995_CR77","unstructured":"Actonel\u00ae package insert (sanofi-aventis 2007)"},{"key":"BFncpuro0995_CR78","unstructured":"Boniva\u00ae package insert (Roche Laboratories, Inc. 2006)"},{"key":"BFncpuro0995_CR79","unstructured":"ClinicalTrials.gov [\n                    http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00329797?order=1\n                    \n                  ] (accessed 15 May 07)"},{"key":"BFncpuro0995_CR80","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0022-5347(01)69080-3","volume":"167","author":"D Scherr","year":"2002","unstructured":"Scherr D  et al. (2002) Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 167: 535\u2013538","journal-title":"J Urol"},{"key":"BFncpuro0995_CR81","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1210\/jc.2002-020539","volume":"7","author":"P Taxel","year":"2002","unstructured":"Taxel P  et al. (2002) The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 7: 4907\u20134913","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpuro0995_CR82","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/ncpuro0326","volume":"2","author":"PD Smith","year":"2005","unstructured":"Smith PD (2005) Therapy insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol 2: 608\u2013615","journal-title":"Nat Clin Pract Urol"},{"key":"BFncpuro0995_CR83","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE  et al. (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042\u20134057","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"BFncpuro0995_CR84","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1007\/s001980070007","volume":"11","author":"PD Delmas","year":"2000","unstructured":"Delmas PD (2000) Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11 (Suppl 6): S66\u2013S76","journal-title":"Osteoporos Int"},{"key":"BFncpuro0995_CR85","unstructured":"Medicare Coverage Database. Centers for Medicare & Medicaid Services [\n                    http:\/\/www.cms.hhs.gov\/mcd\/viewlcd.asp?lcd_id=23694&lcd_version=4&\u00a0show=all\n                    \n                  ] (accessed 15 May 2007)"}],"container-title":["Nature Clinical Practice Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpuro0995","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpuro0995.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpuro0995.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T16:18:26Z","timestamp":1684426706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpuro0995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["BFncpuro0995"],"URL":"https:\/\/doi.org\/10.1038\/ncpuro0995","relation":{},"ISSN":["1743-4270","1743-4289"],"issn-type":[{"value":"1743-4270","type":"print"},{"value":"1743-4289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}